EVA Pharma’s roots stretch back over a hundred years.

Our History

Our experienced leadership team keeps us on track.

Meet our Leaders

EVA Pharma’s success is based on its dynamic team, Our people are our power.

Life at EVA Pharma

Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases across 49 low- to middle-income countries in Africa&nbsp;
INDIANAPOLIS, CAIRO, September 4, 2024 -- Eli Lilly and Company (NYSE: LLY) and EVA Pharma announced today that the companies have entered into an agreement to expand access to baricitinib to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. Discovered by Incyte and licensed to Lilly, baricitinib is for the treatment of rheumatoid arthritis, alopecia areata, atopic dermatitis, and COVID-19.&nbsp;This collaboration is part of the Lilly 30x30 initiative, which aims to improve access to quality health care for 30 million people living in resource-limited settings annually by 2030.&nbsp;
"Our commitment to expanding access to affordable and innovative medicines for people living in low- to middle-income countries continues,” said Ilya Yuffa, executive vice president and president of Lilly International. “Following our collaboration with EVA Pharma on insulin manufacturing, we are now establishing the first of its kind voluntary licensing agreement for Lilly, where the company will provide certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply baricitinib to people in 49 countries across Africa.”&nbsp; &nbsp;
“We are proud to localize the entire value chain of this critical medication on the continent, from producing high-potency baricitinib active pharmaceutical ingredient (API), to tackling complex manufacturing challenges.” said Riad Armanious, CEO of EVA Pharma.&nbsp;
EVA Pharma’s dedicated high-containment facility is set to begin sales of the locally manufactured baricitinib by 2026 to various African countries.&nbsp;
This collaboration announced today relies on both EVA’s pan-African reach and its strong local manufacturing capabilities that meet global standards, enabling Lilly to reach more people in low- to middle-income countries.&nbsp;
Since 2021, EVA Pharma has been working with Lilly to ensure a sustainable supply of life-saving medicines across several African countries. Lilly and EVA Pharma are also collaborating to expand access to affordable insulin in 56 countries, most of which are low- to middle-income, as announced in 2022.&nbsp;
About Lilly&nbsp;
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. C-LLY&nbsp;
About EVA Pharma&nbsp;
EVA Pharma empowers the fight for health and well-being in communities around the world. With a 5,000-strong team of professionals, the company produces more than one million healthcare products a day at its state-of-the-art manufacturing facilities, which are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple regulatory agencies.&nbsp;
The company’s product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand.&nbsp;
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 40 countries worldwide.&nbsp;
For more information, please visit: www.evapharma.com &amp; https://www.evapharma.com/newsroom or follow us on Facebook, LinkedIn &amp; Instagram  &nbsp;
Cautionary Statement Regarding Forward-Looking Statements&nbsp;
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the agreement with EVA Pharma where Lilly will license certain manufacturing know-how and reflects Lilly’s current beliefs and expectations. However, there can be no assurance that the agreement will achieve Lilly’s objectives or that Lilly will execute its strategy&nbsp;

Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries

04 Sep, 2024

Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries

04 Sep, 2024

Find out more about EVA Pharma

EVA Pharma’s roots stretch back over a hundred years.

Our experienced leadership team keeps us on track.

EVA Pharma’s success is based on its dynamic team, Our people are our power.

© 2022 Eva Pharma All Rights Reserved - شركة ايفا فارما للادوية و المستلزمات الطبية